ERBB2 and breast carcinoma: Importantly, the development of the monoclonal anti-HER2 antibody trastuzumab has been shown to have a substantial clinical benefit, inhibiting tumor progression by targeting the HER2 receptor in early and metastatic breast-cancer patients [3,4].